-
Kenya's economy faces climate change risks: World Bank
-
Japan puts the heat on suspected ice cream cartel
-
Sovereignty fears to dog AI enthusiasm at France's Vivatech
-
MEXC May Report: SPACEX Launchpad Oversubscribed 15.5x, US Equity Futures Volume Jumps 85%
-
MEXC Prediction Markets Launches Combo to Enable Multi-Event Combination Trading
-
'We have always won': Ebola pioneer still on front line at 84
-
Trap, neuter, release: Jakarta battles cat-astrophic stray numbers
-
US Fed set to hold rates steady at Warsh's first meeting in charge
-
Spanish actor Javier Bardem leaves his mark on Hollywood Boulevard
-
After three sessions, SpaceX already among world's most valuable companies
-
Surging SpaceX overtakes Amazon to become 5th biggest company
-
BMW downgrades 2026 targets on Mideast war, China woes
-
German court bans McDonald's from making climate claim
-
Campaigners urge G7 chiefs to protect children from AI risks
-
Like father, like son: Prince George to attend Eton College
-
Paris store to part ways with Shein after ownership change
-
US Federal Reserve kicks off first meeting with Warsh as chair
-
How can France-UK mission help reopen Strait of Hormuz?
-
EU to ban plant-based 'steaks' but veggie 'burgers' sizzle on
-
Russian oil producer rations fuel as Ukraine attacks bite
-
EU clears major hurdle on US tariff deal
-
Mideast war peace deal boosts German investor morale
-
Iran says talks on final US deal to begin this week
-
With feasts and music, Kashmiri weddings keep traditions alive
-
French spies drop AI giant Palantir over US overreliance fears
-
India blocks Telegram before retest exam to curb cheating
-
Bank of Japan hikes interest rate to 31-year high
-
Stocks extend rally, oil flat as peace optimism builds
-
Deadline looms for UniCredit's hostile bid for Commerzbank
-
Bank of Japan hikes rate to 31-year high
-
Scientist confronting the rising global threat of mosquitoes
-
India eyes biofertilisers after Mideast war stoked supply fears
-
Most stocks rise, oil flat following peace deal-fuelled rally
-
Toxic 'time bomb' threatens Mekong river basin
-
EU nears finish line on US tariff deal
-
Social networks, online video outweigh traditional media in 2026
-
Trump says Hormuz to 'completely open' after US-Iran peace deal
-
Timeline of Trump-linked resort project in Albania
-
IMF chief warns energy recovery to take time after US-Iran ceasefire
-
Launch 3 Telecom Secures New Lakeland Facility
-
'Start your engines'? Shipping groups wary on Hormuz reopening
-
US-Iran deal met with hope, scepticism in Mideast
-
German working-age population to shrink dramatically: study
-
'For sure': Macron to preach stronger Europe vision at G7 swansong
-
Crude prices plunge, stocks surge on US-Iran peace deal
-
Starbucks Korea to shutter outlets for history lessons after 'Tank Day' fiasco
-
Courts cracking down on error-strewn AI-assisted legal briefs
-
Bitter communion: Cuban priests ordered to ration mass wafers
-
In crisis-hit Cuba, World Cup offers brief respite
-
UK intercepts Russian shadow fleet vessel in Channel
'We have always won': Ebola pioneer still on front line at 84
In 1976, young Congolese doctor Jean-Jacques Muyembe was sent to a remote village to look into a mysterious illness and found himself confronting Ebola, a deadly virus the world did not yet know.
Just back in the Democratic Republic of Congo after studying in Belgium, he had been called to Yambuku where doctors initially thought they were dealing with typhoid or yellow fever.
He drew blood from a sick nun and sent the sample to Belgium where microbiologist Peter Piot would soon isolate the new virus, later named Ebola after a nearby river.
At the time, Muyembe had little sense of the danger he had exposed himself to.
"When I removed the needle, the blood kept flowing and my fingers were covered in it," he told AFP in Kinshasa.
"We had no gloves, no gowns, no masks as we do today."
Fifty years later, and now aged 84, Muyembe is still on the front line against a virus he helped uncover as the DRC battles its 17th deadly outbreak.
Despite the scale of the crisis, with 808 people infected and 192 killed in the country, according to the World Health Organization, he stressed: "We have always won the battle against Ebola."
- Animals to humans -
The latest outbreak, declared on May 15, has mainly hit the remote, conflict-weary northeastern Ituri province.
Causing it is the Bundibugyo strain, for which there is currently no vaccine or treatment, unlike the more common Zaire strain, against which vaccines were developed in 2018 and 2019.
But "the lack of a vaccine does not mean the battle is lost," said Muyembe, who heads the state-run National Institute of Biomedical Research (INRB).
On his desk is a medal and photographs of him with dignitaries, as well as piles of letters from international partners and donors.
He pointed out that the DRC had overcome 15 Ebola outbreaks in the past using public health measures alone, long before vaccines and modern treatments were available.
Muyembe also said he was pleased to see African scientists, once reliant on foreign labs, play a key role in responding to outbreaks on the continent.
Still, health authorities in the DRC have faced criticism this time for delays in detecting the outbreak and in supporting overstretched frontline workers.
In recent weeks, fearing border closures, the government has insisted that the situation is under control.
Also lying on Muyembe's desk is an open file on mpox -- a reminder that Ebola is only one of several threats facing the DRC.
Muyembe believes the crises are linked. The country's exceptional biodiversity, combined with deforestation and climate change, has pushed communities deeper into the forests, and into closer contact with wildlife.
It makes the DRC "particularly vulnerable to epidemics of zoonotic diseases" that pass from animals to humans, like Ebola and mpox, he said.
- 'Greatest risk' -
After the initial 1976 outbreak, Ebola disappeared for nearly two decades, returning in 1995 in the western city of Kikwit, where it appeared as an outbreak of "red diarrhoea".
Drawing on his experience, Muyembe experimented by treating eight patients with blood transfusions from survivors.
Seven of them lived. The sample was small, but the concept laid the groundwork for a line of research that would eventually lead to the development of Ebanga, the first approved Ebola treatment, licensed in 2020.
Now a father of nine and grandfather to many, Muyembe reflected on that first mission as a young graduate freshly returned to the DRC.
Looking back, the virologist said he took "the greatest risk of my life" that day.
"I took part in identifying the virus and in treating the disease," the virologist said. "What more can one do in a lifetime?"
H.Cho--CPN